Pharvaris Publishes Decades-Long Evidence Supporting Bradykinin B2 Receptor as Key Therapeutic Target
Event summary
- Pharvaris published a review article in Clinical Reviews in Allergy & Immunology summarizing decades of evidence supporting bradykinin B2 receptor antagonism as a therapeutic strategy for bradykinin-mediated diseases.
- The article highlights the role of bradykinin B2 receptor in conditions like hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
- Pharvaris aims to develop oral bradykinin B2 receptor antagonists with injectable-like efficacy for treating bradykinin-mediated angioedema.
- The publication underscores the potential of bradykinin B2 receptor antagonism for a broader range of immunological and inflammatory disorders.
The big picture
Pharvaris' publication underscores the strategic importance of bradykinin B2 receptor antagonism in treating bradykinin-mediated diseases. The review article consolidates decades of research, positioning Pharvaris as a leader in developing novel oral therapies for conditions like HAE and AAE-C1INH. This move aligns with broader industry trends towards mechanism-based treatment approaches, potentially broadening the therapeutic landscape for inflammatory and immunological disorders.
What we're watching
- Clinical Validation
- How the growing body of evidence will influence regulatory approvals and market acceptance of Pharvaris' bradykinin B2 receptor antagonists.
- Therapeutic Expansion
- Whether Pharvaris can successfully expand the use of bradykinin B2 receptor antagonism to other immunological and inflammatory disorders beyond HAE and AAE-C1INH.
- Competitive Dynamics
- The pace at which competitors develop similar therapies, potentially impacting Pharvaris' market position.